AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05894538
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use.
Trial: NCT05249881
Drug: Semaglutide Pen Injector
RxNorm normalized name: semaglutide Pen Injector
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All Diabetes mellitus type2 patients fulfilling the inclusion criteria, will receive 0.25mg Semaglutide injection per week and after two weeks dosage will be escalated to 0.5 mg/week for next 10 weeks.
Trial: NCT06126952
Drug: Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair)
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 sprays per nostril of Azelastine 0.15% twice daily.~Total dose of active drug:~1644 mcg azelastine hydrochloride per day
Trial: NCT06126952
Drug: Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 sprays per nostril of Ryaltris twice daily.~Total dose of active drug:~200 mcg mometasone furoate and 4800 mcg olopatadine per day
Trial: NCT05256342
Drug: Duloxetine 60mg
RxNorm normalized name: DULOXETINE 60MG CAP,SPRINKLE,EC
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eight weeks treatment, one pill daily.~1st week 30mg; weeks 2-7th -- 60 mg daily.
Trial: NCT05256342
Drug: omeprazol
RxNorm normalized name: Omeprazol
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg daily; will be taken with Etoricoxib from the second week of treatment
Trial: NCT05908526
Drug: suvorexant (or placebo)
RxNorm normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA approved which is an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Trial: NCT06044805
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Total of 25mg base per kg over 3 days (10 mg base/kg on Days 0 and 1, 5 mg base/kg on Day 2)
Trial: NCT06044805
Drug: Primaquine
RxNorm normalized name: Primaquine
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Primaquine: 7.5 mg base tablet. Medication given as 0.25mg/kg daily for 14 days.
Trial: NCT05941338
Drug: Tirelizumab ,+Carboplatin+albumin-bound paclitaxel
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sintilimab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days. Intervention: Drug: Sintilimab , Carboplatin, albumin-bound paclitaxel
Trial: NCT06455410
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a PD-L1 inhibitor
Trial: NCT04819438
Drug: Riluzole 50 mg Oral Film
RxNorm normalized name: riluzole 50 MG Oral Film
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before each administration, the subjects will drink 20 mL of still mineral water in order to wet their mouth. Afterwards, using gloves, the investigator or deputy will take the orodispersible film (32.0x22.0 mm) out of the provided pouch and place the product directly on the top surface (dorsal aspect) of the subjects' tongue.
Trial: NCT04819438
Drug: Rilutek 50Mg Tablet
RxNorm normalized name: Rilutek 50mg Tablet
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One film-coated tablet will be swallowed (without chewing) with 150 mL of still mineral water.
Trial: NCT06099418
Drug: Atezolizumab Injection [Tecentriq]
RxNorm normalized name: atezolizumab Injection [Tecentriq]
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous (IV) infusions of atezolizumab (saline solution) every 3 weeks.
Trial: NCT05422781
Drug: ITI-3000
RxNorm normalized name: Arthur Itis
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ITI-3000 is a DNA vaccine (L-H LT S220A) which contains sequences for both LAMP1 and LTS220A, the truncated form of the LT antigen of MCPyV with a detoxifying serine to alanine mutation at position 220
Trial: NCT05523596
Drug: ICM20
RxNorm normalized name: Icodextrin
DrugBank: Icodextrin (DB00702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: small molecules
Trial: NCT05523596
Drug: Benznidazole
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: small molecule
Trial: NCT00481559
Drug: Voraxaze (glucarpidase)
RxNorm normalized name: Voraxaze
DrugBank: Glucarpidase (DB08898)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50 Units/kg in a bolus intravenous injection over 5 minutes
Trial: NCT06434662
Drug: mitoxantrone hydrochloride liposome
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitoxantrone hydrochloride liposome (24 mg/m\^2) on day 1, every 4 weeks
Trial: NCT06434662
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine (1.0 g/m\^2, q12h ) on day 1,3,5, every 4 weeks
Trial: NCT06434662
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax 100 mg on day 2，200 mg on day 3，400 mg on day 4-10, every 4 weeks
Trial: NCT06067048
Drug: Zanubrutinib Oral Capsule
RxNorm normalized name: zanubrutinib Oral Capsule
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 cycles (1 cycle is 28 days)
Trial: NCT04698785
Drug: Treatment by regorafenib and best supportive care
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment for 13 cycles (12 months) maximum.~During each cycle :~* patients ≥ 16 years old and patients \<16 old with Body Surface Area (BSA) ≥ 1,70 m2 will take 3 tablets, once a day, corresponding to a total of 120 mg Regorafenib, during 21 days, followed by 7 days without treatment.~* patients \< 16 years old with a 1,30 m2 ≤ BSA ≥ 1,70 m2 will take 2 tablets, once a day, corresponding to a total of 80 mg Regorafenib, during 21 days, followed by 7 days without treatment
Trial: NCT05569538
Drug: Bomedemstat
RxNorm normalized name: Bomedemstat
DrugBank: Bomedemstat (DB17234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bomedemstat will be self-administered orally once daily. In both cohorts, the dose of bomedemstat will be adjusted in each patient based on titration of the patient's platelet count to the target range. Ruxolitinib will be self-administered orally. Both medications will continue uninterrupted in 28-day cycles. Subjects will continue combination treatment through the Initial Treatment Period (first 6 cycles), which includes a Qualification Assessment. Those deriving clinical benefit in the opinion of the treating physician may continue receiving combination treatment in the Additional Treatment Period (6 cycles). Qualification Assessments will be performed at the end of each Additional Treatment Period, which is iterative, and may repeat for as long as clinical benefit is sustained, at the discretion of the treating physician.
Trial: NCT05192629
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Premedication by intranasal dexmedetomidine
Trial: NCT05192629
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Premedication by intranasal midazolam
Trial: NCT06607367
Drug: Ruxolitinib (JAKAVI®)
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial starting dose will be 10mg BD
Trial: NCT06607367
Drug: Eltrombopag (Revolade®)
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Initial starting dose will be 50mg daily
Trial: NCT06607926
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg, IV, d1 of each 21-d cycle, four cycles
Trial: NCT06607926
Drug: Platinum-doublet chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen: (1) for squamous cell carcinoma: cisplatin/carboplatin + paclitaxel; and (2) for non-squamous cell carcinoma: cisplatin/carboplatin + pemetrexed.
Trial: NCT05184101
Drug: Unfractionated Heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin sodium will be administered as a nebulised aerosol dose of 25,000 IU heparin three times a day (TDS) via an Aerogen Solo (Aerogen, Ireland) vibrating mesh aerosol drug nebulizer.
Trial: NCT06194955
Drug: GLP-1
RxNorm normalized name: rGLP-1
DrugBank: rGLP-1 (DB05433)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion
Trial: NCT06194955
Drug: GLP-2
RxNorm normalized name: (Gly2)GLP-2
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infusion
Trial: NCT04644796
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients included in the treatment group will have their incisional site infused, targeting the paraspinal muscles with liposomal bupivacaine at the end of their surgery.
Trial: NCT04782245
Drug: Dapagliflozin 10mg
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The intervention group will receive, during 6 months, dapagliflozin per oral route at a dose of 10 mg once daily in addition to the optimal medical management based on current heart failure practice guidelines.
Trial: NCT04862949
Drug: Atezolizumab plus bevacizumab
RxNorm normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Atezolizumab plus bevacizumab
Trial: NCT05685732
Drug: Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
RxNorm normalized name: dexmethylphenidate and serdexmethylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Trial: NCT04855955
Drug: Adipose-Derived Mesenchymal Stem Cells
RxNorm normalized name: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins
DrugBank: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins (DB15729)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04947631
Drug: DKF-313
RxNorm normalized name: DKFZ-PSMA-11 Ga-68
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dutasteride 0.5 mg and tadalafil 5 mg once daily for 48 weeks
Trial: NCT04947631
Drug: Dutasteride
RxNorm normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dutasteride 0.5 mg once daily for 48 weeks
Trial: NCT04947631
Drug: Tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg once daily for 48 weeks
Trial: NCT04947631
Drug: Dutasteride placebo
RxNorm normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily for 48 weeks
Trial: NCT04947631
Drug: Tadalafil placebo
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily for 48 weeks
Trial: NCT06119880
Drug: Pancreatin Enteric-coated Capsules
RxNorm normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pancreatic enzyme replacement therapy
Trial: NCT04580277
Drug: Tofacitinib 10 mg
RxNorm normalized name: tofacitinib 10 MG
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects in this arm will receive tofactinib 10 mg twice daily for 8 weeks
Trial: NCT04932213
Drug: Tropicamide Ophthalmic
RxNorm normalized name: tropicamide ophthalmic
DrugBank: Tropicamide (DB00809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tropicamide eye drops are used for dilating pupils (mydriasis) to do comprehensive fundus examination.
Trial: NCT05254405
Drug: Brexanolone Injection [Zulresso]
RxNorm normalized name: brexanolone Injection [Zulresso]
DrugBank: Brexanolone (DB11859)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous infusion of brexanolone over 60 hours titrated to a maximal dose of 90 mcg/kg/hr.
Trial: NCT05296460
Drug: Dapsone gel
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients will use topical dapsone gel 7.5% once daily on left side of face ,The patients will use TCA20% peeling as a peeling session every 2 weeks (6 sessions) on right side of face
Trial: NCT06605911
Drug: topical triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ten patients with OLP were received topical triamcinolone acetonide four times per day for six weeks
Trial: NCT06605911
Drug: Topical Curcumin
DrugBank: Cumin (DB10864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ten patients with OLP received topical curcumin four times per day for six weeks.
Trial: NCT06605911
Drug: topical triamcinolone acetonide combiend with topical curcumin
RxNorm normalized name: triamcinolone acetonide Topical Ointment
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ten patients with OLP received a combination of topical triamcinolone acetonide and topical curcumin four times per day for six weeks.
Trial: NCT05176002
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant Camrelizumab combined with radiotherapy
Trial: NCT05628506
Drug: Potassium iodide
RxNorm normalized name: Potassium Iodide
DrugBank: Potassium Iodide (DB06715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive a single oral administration of a pharmacological dose (97.5 mg) of potassium iodide 20±4 hours before surgery.
Trial: NCT04924036
Drug: glycopyrronium cloths
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qbrexza is an anticholinergic indicated for topical treatment of axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Trial: NCT06225024
Drug: BoNT A
RxNorm normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT-A is widely recognized as the benchmark for enhancing the effectiveness of spasticity management
Trial: NCT05180318
Drug: Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato]
RxNorm normalized name: ESKETAMINE HYDROCHLORIDE 28 mg in 0.2 mL NASAL SOLUTION [Spravato]
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esketamine (0.25 mg/kg) will be given intravenously 24-36 hours before surgery (infusion time: 40 min) and immediately after surgery (infusion time: 40 min).
Trial: NCT05244460
Drug: Droperidol Injectable Product
RxNorm normalized name: droperidol Injectable Product
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment
Trial: NCT05244460
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment
Trial: NCT05450887
Drug: UDCA
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA：13\~15 mg/kg/day
Trial: NCT05807776
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 200mg, iv, d1, Q3W
Trial: NCT05807776
Drug: Tislelizumab, Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tislelizumab combined with lenvatinib:~Tislelizumab 200mg, iv, d1, Q3W Lenvatinib 8mg，po，qd.
Trial: NCT00000627
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03211793
Drug: Mesenchymal stromal cells
RxNorm normalized name: Mesenchymal Stromal Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
Trial: NCT05238012
Drug: Atorvastatin Calcium Tablets
RxNorm normalized name: Atorvastatin Calcium Tablets
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin Calcium Tablets, 20mg/day, once a day, one tablet each time, before bedtime;
Trial: NCT00363792
Drug: Glyceryl trinitrate, azetazolamide
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05628922
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early Responders: They receive the second and third cycle of induction chemotherapy (GP regimen), followed by cisplatin-based concurrent chemoradiation.~Intermediate Responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w \* 2 cycles), followed by cisplatin-based concurrent chemoradiation.~Late responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w \* 2 cycles), followed by cisplatin-based concurrent chemoradiation. At 4-6 weeks post-chemoradiation, they received adjuvant capecitabine and toripalimab for 6 months.
Trial: NCT05300685
Drug: Basic buccal procedure + Buccal block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Addition of long-acting local anesthetic as a buccal block after oral graft harvest
Trial: NCT00002368
Drug: Nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002368
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04914390
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg on d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.
Trial: NCT06055465
Drug: Sacituzumab Govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * 4 cycles, each cycle lasting for 3 weeks~* 10mg/kg given every day 1 and day 8 each cycle~* IV infusion
Trial: NCT06055465
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * 4 cycles, each cycle lasting for 3 weeks in Neoadjuvant phase; after surgery, 13 cycles, each cycle lasting for 3 weeks in Maintenance phase.~* 200mg fixed dose every day 1 each cycle~* IV infusion
Trial: NCT04914390
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8mg on d1-14 of Cycles 1-5 (Q3W) of the neoadjuvant phase of the study; po. Arotinib is a small molecule multi-target TKI, which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.
Trial: NCT06008366
Drug: 7MW3711 for injection
RxNorm normalized name: 7MW3711
DrugBank: 7MW3711 (DB19298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration of 7MW3711, Q3W, 3 weeks a cycle
Trial: NCT04677426
Drug: Hyperpolarized Xe129
RxNorm normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to assess patients with cHP and IPF.
Trial: NCT06066905
Drug: chidamide and azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: chidamide：10mg orally,day 1 to day 6 every week, Take it for two weeks, rest for two weeks,so 28 days for a circle, 12 circles totally.~azacitidine:50mg,subcutaneous injection,day 1 to day 5 every week, 28 days for a circle, 6 circles totally.
Trial: NCT06008366
Drug: 7MW3711 for injection
RxNorm normalized name: 7MW3711
DrugBank: 7MW3711 (DB19298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1
Trial: NCT06155734
Drug: Fluorescence guided identification using indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Fica (DB03384)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During minimally invasive surgery using intravenous administration of indocyanine green (ICG) near-infrared fluorescence imaging will be applied to identify and treat paragangliomas
Trial: NCT06375642
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab, Surufatinib and HAIC
Trial: NCT05513664
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 or 160 mg/qd
Trial: NCT05388773
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV.
Trial: NCT05388773
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV